We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Inhaled Furosemide Versus Placebo for Acute Viral Bronchiolitis in Hospitalized Infants

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00261937
First Posted: December 6, 2005
Last Update Posted: February 6, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Bnai Zion Medical Center
December 5, 2005
December 6, 2005
February 6, 2013
December 2005
Not Provided
Clinical respiratory effects
Same as current
Complete list of historical versions of study NCT00261937 on ClinicalTrials.gov Archive Site
  • 1. The duration of hospitalization
  • 2. Time weaned off oxygen
  • 3. Time to full enteral feeding
Same as current
Not Provided
Not Provided
 
Inhaled Furosemide Versus Placebo for Acute Viral Bronchiolitis in Hospitalized Infants
Inhaled Furosemide Versus Placebo for Acute Viral Bronchiolitis in Hospitalized Infants
We hypothesize that inhaled Furosemide will be an effective treatment in infants with acute bronchiolitis.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Bronchiolitis
Drug: Inhaled Furosemide vs Placebo (Normal Saline)
Not Provided
Bar A, Srugo I, Amirav I, Tzverling C, Naftali G, Kugelman A. Inhaled furosemide in hospitalized infants with viral bronchiolitis: a randomized, double-blind, placebo-controlled pilot study. Pediatr Pulmonol. 2008 Mar;43(3):261-7. doi: 10.1002/ppul.20765.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
April 2006
Not Provided

Inclusion Criteria:

  • Age: 0-12 months.
  • Infants who are otherwise healthy
  • Infants with chronic lung disease of prematurity (BPD) will be included, but will be analyzed separately.
  • Parents signed a written informed consent.

Exclusion Criteria:

  • • Other previous or co-morbidity, specifically: respiratory (other than BPD, like Asthma or Cystic Fibrosis), cardiac or renal disease or anomaly.
Sexes Eligible for Study: All
up to 12 Months   (Child)
No
Contact information is only displayed when the study is recruiting subjects
Israel
 
 
NCT00261937
67/05
Not Provided
Not Provided
Not Provided
Not Provided
Bnai Zion Medical Center
Not Provided
Principal Investigator: Amir Kugelman Bnai Zion Medical Center
Bnai Zion Medical Center
December 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP